Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases

Table 1 Patient characteristics for the complete cohorts or the IFN^high selection

		SLE	IFNβ-treated MS^b	Untreated MS	IIM	RA	Healthy controls
Total amount	All	47	71	160	78	76	54
Total amount	IFN^high	30	63	12	26	10
Age in years, mean (SD)	All	44 (14)	34 (8)	36 (10)	56 (14)	54 (13)	35 (10)
Age in years, mean (SD)	IFN^high	42 (13)	35 (8)	34 (9)	55 (17)	52 (16)
Female, %	All	85	73	67	62	79	53
Female, %	IFN^high	93	72	83	69	89
Disease activity, mean (SD)^a	All	4 (5)	n.a	n.a.	n.a.	4.8 (1.4)^c	n.a.
Disease activity, mean (SD)^a	IFN^high	5 (5)	n.a	n.a.	n.a.	5.3 (1.6)^d	n.a.
Current prednisolone use, %	All	50	n.a.	n.a.	70	17	n.a.
Current prednisolone use, %	IFN^high	57	n.a.	n.a.	60	22
Current use of other immunomodulatory drugs, %	All	63	n.a.	n.a.	60	24	n.a.
Current use of other immunomodulatory drugs, %	IFN^high	67	n.a.	n.a.	56	33

^aDisease activity scores: for systemic lupus erythematosus (SLE), the Systemic Lupus Erythematosus Disease Activity Index; for rheumatoid arthritis, the Disease Activity Score in 28 joints. ^bPatients with a type I interferon (IFN) signature (IFN ^high) (see Fig. 1) before start of therapy were not included in the IFN^high selection of this cohort. ^cdata missing from 5 patients. ^ddata missing from 1 patient All refers to the complete cohort. MS multiple sclerosis, IIM idiopathic inflammatory myopathies, SD standard deviation, n.a. not applicable

ISSN: 1478-6362